Categories Earnings, Health Care

Aurinia Pharmaceuticals (NASDAQ: AUPH): Q4 2019 Earnings Snapshot

— Aurinia Pharmaceuticals (NASDAQ: AUPH) reported a fourth-quarter 2019 loss of $0.78 per share versus a loss of $0.14 per share expected.

— Revenue remained flat at $29,000 versus $40,000 expected. The top line was hurt by nil contract revenue.

Earnings Update by AlphaStreet

— The bottom line was hurt by an increase in the estimated fair value of derivative warrant liabilities.

— Research and development expenses increased by 23% due to costs related to NDA submission preparation costs, higher personnel costs, higher costs incurred for the Aurora 2 extension trial, and the Audrey DES phase 2/3 study.

— During the second half of 2020, the company anticipates reporting interim data from the exploratory Phase 2 FSGS study and results from the Phase 2/3 Audrey DES trial evaluating 3 concentrations of VOS compared to the vehicle alone.

— The company believes it has sufficient financial resources to fund its current plans. This includes ongoing R&D programs, completing the NDA submission, manufacturing and packaging commercial drug supply required for launch, and fund its supporting corporate and working capital needs through 2021.

Listen to on-demand earnings calls and hear how management responds to analysts’ questions

Most Popular

Mattel (MAT): A look at the toymaker’s expectations for the year

Shares of Mattel, Inc. (NASDAQ: MAT) were up slightly on Thursday. The stock has gained 20% year-to-date and 19% over the past three months. There is a level of optimism

Earnings Preview: Paychex likely to report higher Q1 revenue and profit

Paychex Inc. (NASDAQ: PAYX), a leading provider of human capital management solutions, is all set to publish operating results for the first three months of fiscal 2024. The company has

DRI Earnings: Key quarterly highlights from Darden Restaurants’ Q1 2024 financial results

Darden Restaurants, Inc. (NYSE: DRI) reported first quarter 2024 earnings results today. Total sales increased 11.6% to $2.73 billion compared to the same period last year. Blended same-restaurant sales were

Add Comment
Loading...
Cancel
Viewing Highlight
Loading...
Highlight
Close
Top